Clinical Scorecard: FDA Monthly Preview: Key April Decisions to Watch
At a Glance
Category
Detail
Condition
Various conditions including aneurysmal subarachnoid hemorrhage, Alzheimer's disease agitation, focal segmental glomerulosclerosis, stage 2 type 1 diabetes, and HIV-1 infection.
Key Mechanisms
Involves novel therapies and label expansions across multiple specialties.
Target Population
Patients with specific conditions as mentioned for each investigational therapy.
Care Setting
Outpatient and inpatient settings depending on the condition.
Key Highlights
GTx-104 accepted for review for aneurysmal subarachnoid hemorrhage with a PDUFA date of April 23, 2026.
AXS-05 accepted for priority review for Alzheimer's disease agitation with a PDUFA date of April 30, 2026.
Sparsentan's review extended for focal segmental glomerulosclerosis with a PDUFA date of April 13, 2026.
Teplizumab accepted for priority review to delay progression of type 1 diabetes in children with a PDUFA date of April 29, 2026.
Doravirine/Islatravir under review for HIV-1 treatment with a PDUFA date of April 28, 2026.
Guideline-Based Recommendations
Diagnosis
Monitor patients for specific conditions as per clinical guidelines.
Management
Consider investigational therapies as they become available based on FDA decisions.
Monitoring & Follow-up
Evaluate safety and efficacy through ongoing clinical trials.
Risks
Assess potential adverse events associated with new therapies.
Patient & Prescribing Data
Patients with aneurysmal subarachnoid hemorrhage, Alzheimer's disease agitation, focal segmental glomerulosclerosis, stage 2 type 1 diabetes, and HIV-1 infection.
Investigational therapies show promise in reducing symptoms and improving outcomes.
Clinical Best Practices
Stay updated on FDA decisions and emerging therapies.
Incorporate findings from clinical trials into patient management plans.
Engage in shared decision-making with patients regarding new treatment options.
